Shares of Invuity, Inc. (NASDAQ:IVTY) have earned a consensus rating of “Buy” from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $11.00.

Several equities research analysts have commented on IVTY shares. Zacks Investment Research lowered shares of Invuity from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. ValuEngine upgraded shares of Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Piper Jaffray Companies restated a “buy” rating and set a $10.00 target price on shares of Invuity in a research report on Wednesday, July 26th. Finally, Northland Securities restated a “buy” rating and set a $13.00 target price on shares of Invuity in a research report on Tuesday, September 26th.

COPYRIGHT VIOLATION WARNING: “Invuity, Inc. (IVTY) Receives Average Recommendation of “Buy” from Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/22/invuity-inc-ivty-receives-average-recommendation-of-buy-from-brokerages.html.

Invuity (NASDAQ IVTY) traded up 6.25% during trading on Friday, reaching $9.35. 52,688 shares of the company’s stock were exchanged. Invuity has a 52 week low of $4.50 and a 52 week high of $11.43. The stock has a 50-day moving average price of $8.69 and a 200 day moving average price of $8.69. The firm’s market capitalization is $159.42 million.

Invuity (NASDAQ:IVTY) last issued its earnings results on Tuesday, July 25th. The medical instruments supplier reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.07). The company had revenue of $9.77 million for the quarter, compared to analysts’ expectations of $10.30 million. Invuity had a negative return on equity of 140.69% and a negative net margin of 114.61%. Equities research analysts forecast that Invuity will post ($2.38) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Invuity during the 2nd quarter worth $101,000. UBS Group AG boosted its position in shares of Invuity by 53.4% during the 1st quarter. UBS Group AG now owns 13,200 shares of the medical instruments supplier’s stock worth $105,000 after purchasing an additional 4,594 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Invuity during the 1st quarter worth $151,000. Spark Investment Management LLC purchased a new stake in shares of Invuity during the 2nd quarter worth $158,000. Finally, Boston Advisors LLC boosted its position in shares of Invuity by 55.6% during the 2nd quarter. Boston Advisors LLC now owns 28,280 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 10,111 shares in the last quarter. Institutional investors own 68.87% of the company’s stock.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.